Endpoints News – The biopharma world is here

SUBSCRIBE

top stories

Stepping on Roche's toes, Merck cuts into SCLC niche with third-line Keytruda OK

4 hours ago

After watching its share price soar on a Bloomberg report and heated rumors, Biohaven stock takes a billion-dollar ...

6 hours ago

The top 10 blockbuster drugs in the late-stage pipeline — Evaluate adds 6 new therapies to heavy-hitter list

8 hours ago

Latest

Most read

UPDATED: Pfizer CEO Albert Bourla is back in the M&A game, but why is he paying $11.4B for Array?

Yesterday

Unity's early longevity data look 'encouraging'; Adaptive Biotechnologies looks to raise $200M in IPO

3 hours ago

Study: Just half of postmarketing commitment trials are published

4 hours ago

Right back at you, Pfizer: BeiGene and a Pfizer spinout launch a newco to develop a MEK/BRAF inhibitor that could ...

4 hours ago

see latest stream

People

Under siege, investment manager Woodford faces another investment shock

4 days ago

Turns out, Rudy Tanzi didn't see much of a story about a hidden link between Enbrel and Alzheimer's either

5 days ago

J&J gains an enthusiastic endorsement from President Donald Trump for their big new drug Spravato

5 days ago

Startups

Philadelphia champions life sciences 'co-working,' reviving former GSK campus in $500M makeover

Yesterday

Adding marquee investors, BlackThorn bags $76M to back an AI-driven strategy for precision neuro medicine

5 days ago

OrbiMed-backed Prelude Therapeutics raises $60M to tackle resistance to cancer treatments

6 days ago

Deals

Sanofi aligns itself with Google to streamline drug development

5 hours ago

UPDATED: Sanofi Genzyme deserts gene therapy developer Voyager Therapeutics

Yesterday

UPDATED: As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup

Yesterday

IPOs

Hansoh grabs $1B windfall in the latest China pharma IPO to hit the Hong Kong exchange

Last week

Weeks after raising $40M, Celgene-partnered Inhibrx lays groundwork for nearly $75M public debut

2 weeks ago

Quest for safe muscarinic receptor agonists to tackle disaster prone CNS field steers Karuna to $75M IPO

3 weeks ago

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW

Subscribe to Endpoints News

Premium storiesSee all

Gene therapy R&D deals turn red hot as Big Pharma steps up to play

Yesterday

Biopharma BD teams are speeding into the fast lane — cash in hand — as dealmaking continues to heat up in Q1 ...

Last month

The top 50 biotechs by market cap — and what their CEOs’ compensation deals tell us about biopharma

Last month

The BCMA frenzy: Tracking the 37 drugs around the world racing to overtake bluebird bio and Celgene

Last month

Don't missSee all

Global Blood Therapeutics poised to submit application for accelerated approval, with new pivotal data on its sickle ...

4 days ago

Gene therapies seize the top of the list of the most expensive drugs on the planet — and that trend has just begun

5 days ago

As another antibiotics biotech sinks into a crisis, warnings of a sector ‘collapse’

5 days ago

Bain’s biotech team has created a $1B-plus fund — with an eye to more Big Pharma spinouts

6 days ago

Peer review See all

Jun

14

Tariq Kassum jumps from Obsidian to Celsius helm; Quell Therapeutics taps Iain McGill as new CEO

Jun

7

LabCorp selects its new CEO; Pfizer names ex-Genentech vet as new head of oncology R&D

May

31

Updated: Alnylam promotes longtime exec Kevin FitzGerald to CSO; Intellia Therapeutics brings on Laura Sepp-Lorenzino

May

24

Akrevia scoops ex-Arsanis chief René Russo as CEO; Scott Gottlieb jumps back into industry; Seattle Genetics raids AstraZeneca for CCO

May

17

Biogen exec Paul McKenzie heads to CSL as COO; Pulmatrix CEO resigns

R&D channel feed

4 days ago

UPDATED: Bluebird shares sink as analysts puzzle out $1.8M sticker shock and an unexpected delay

Bluebird bio $BLUE has unveiled its price for the newly approved gene therapy Zynteglo (LentiGlobin), which came as a big surprise. And it wasn't the only unexpected twist in today's ...

READ MORE

UPDATED: Roche fields first approval for Rozlytrek in the run-up to a showdown with Bayer, Pfizer

7 hours ago

Investors fret as VBI's hep B vaccine fails key secondary PhIII study goal

Yesterday

latest in R&D

AstraZeneca spinout Viela Bio pockets $75M on its way to BLA for autoimmune drug

Yesterday

Fueled by early success, Enanta paves way for mid-stage RSV study in adult patients later this year

Yesterday

Newsmakers at #EHA19: Regeneron, ArQule track progress on response rates

4 days ago

BeiGene touts 'encouraging' response rates as the Chinese biotech mounts challenge to BTK, PD-1 leaders

4 days ago

FDA warns of one death linked to fecal transplants

4 days ago

see latest stories

Pharma channel feed

8 hours ago

AstraZeneca/Merck win EU approval for frontline maintenance treatment of ovarian cancer, months after FDA endorsement

AstraZeneca and Merck’s PARP inhibitor Lynparza has carved itself a niche in Europe. Five months after getting a speedy approval from the US regulator for frontline maintenance ...

READ MORE

Drugmakers sue HHS for trying to add prices to DTC ads

Yesterday

An incensed Catalyst Pharma sues the FDA, accusing agency of bowing to political pressure and breaking federal law

6 days ago

latest in Pharma

Plagued by delays, AstraZeneca HQ costs soar to £750M as it edges toward 2020 completion

6 days ago

Fresh analysis spotlights cardio benefit of J&J's Invokana in diabetes patients without history of CV disease

6 days ago

Silicon Valley's most anticipated slide deck just dropped. What does it mean for biopharma's digital teams?

6 days ago

Merck grows Keytruda indications with head and neck cancer approval

Last week

With a substantial discount to Catalyst's Firdapse, is Jacobus poised to win physician, payer support for off-label adult LEMS use?

Last week

see latest stories